US Patent No: 6,057,373

Number of patents in Portfolio can not be more than 2000

Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
SYNCHRONEURON, INC.LEXINGTON, MA8

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fogel, Barry S Waban, MA 24 264

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
* 5,604,198 Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents 45 1994
 
Merz + Co. GmbH & Co. (1)
* 5,262,162 Cerebral-activating extract 11 1991
 
THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (1)
* 5,602,150 Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia 14 1995
 
LIPHA (1)
* 4,355,043 Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane 23 1980
 
PODUSLO, JOSEPH F (1)
* 5,670,477 Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents 55 1995
 
CHILDREN'S MEDICAL CENTER CORPORATION (3)
* 5,455,279 Regimen method of mediating neuronal damage using nitroglycerine 15 1993
* 5,747,545 Method of preventing NMDA receptor complex-mediated Neuronal damage 9 1995
* 5,614,560 Method of preventing NMDA receptor-mediated neuronal damage 42 1995
 
CENTER FOR NEUROLOGIC STUDY NOT-FOR-PROFIT RESEARCH FOUNDATION OF CALIFORNIA (1)
* 5,206,248 Method for reducing emotional lability 21 1992
 
MERZ PHARMA GMBH & CO. KGAA (2)
* 5,061,703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 42 1990
* 5,382,601 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof 39 1993
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (3)
* 2002/0165,246 Administration of sleep restorative agents 20 2002
* 2006/0251,717 Memantine Oral Dosage Forms 3 2006
* 2008/0089,859 ADMINISTRATION OF SLEEP RESTORATIVE AGENTS 5 2007
 
YALE UNIVERSITY (2)
8,778,979 Glutamate agents in the treatment of mental disorders 0 2006
* 2006/0270,647 Glutamate agents in the treatment of mental disorders 6 2006
 
Robert J. DeLorenzo (1)
* 2005/0153,930 Inhibition of a novel calcium injury current that forms in nuerons during injury prevents neuronal cell death 0 2004
 
NEURO 3D (1)
* 2006/0276,460 Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns 0 2004
 
Nueronetics, Inc. (1)
7,857,746 System and method to reduce discomfort using nerve stimulation 3 2004
 
WARNER-LAMBERT COMPANY (1)
6,942,876 Analgesic compositions comprising anti-epileptic compounds and methods of using same 5 2002
 
MERZ PHARMA GMBH & CO. KGAA (1)
* 2008/0279,896 Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy 6 2008
 
JUVENTUS BIOSCIENCE, LLC (1)
* 2004/0037,895 Methods of treating involuntary facial spasms and facial wrinkles 1 2003
 
KANGWON NATIONAL UNIVERSITY UNIVERSITY-INDUSTRY COOPERATION FOUNDATION (2)
7,691,874 Neuroprotective properties of dextrorotatory morphinans 0 2005
* 2005/0256,147 NEUROPROTECTIVE PROPERTIES OF DEXTROROTATORY MORPHINANS 5 2005
 
FOREST LABORATORIES, INC. (1)
* 2010/0028,427 IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE 0 2009
 
FOREST LABORATORIES HOLDINGS LIMITED (8)
7,456,224 Method for treating autism 5 2004
* 2006/0002,999 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 14 2005
* 2006/0079,582 Memantine for the treatment of childhood behavioral disorders 0 2005
* 2006/0198,884 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 9 2005
* 2008/0108,643 METHOD FOR TREATING AUTISM 4 2007
* 2009/0048,348 METHOD FOR TREATING AUTISM 1 2008
* 2009/0247,644 MEMANTINE FORMULATIONS 1 2009
8,834,924 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 0 2011
 
EMORY UNIVERSITY (1)
7,375,136 pH-dependent NMDA receptor antagonists 2 2002
 
BHI LIMITED PARTNERSHIP (2)
8,748,656 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid 0 2007
* 2008/0146,642 METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID 1 2007
 
ENDO PHARMACEUTICALS INC. (2)
* 6,187,338 Anticonvulsant containing composition for treating neuropathic pain 63 1999
* 6,406,716 Anticonvulsant containing composition for treating neuropathic pain 7 2001
 
Neuronetics, Inc. (25)
7,153,256 Reducing discomfort caused by electrical stimulation 35 2003
7,614,996 Reducing discomfort caused by electrical stimulation 3 2003
* 2004/0199,042 Reducing discomfort caused by electrical stimulation 0 2003
7,320,664 Reducing discomfort caused by electrical stimulation 17 2004
* 2004/0204,625 Reducing discomfort caused by electrical stimulation 6 2004
6,926,660 Facilitating treatment via magnetic stimulation 30 2004
7,601,115 Seizure therapy method and apparatus 5 2004
* 2005/0261,542 Seizure therapy method and apparatus 59 2004
* 2006/0094,924 System and method to reduce discomfort using nerve stimulation 31 2004
7,824,324 Magnetic core for medical procedures 2 2005
7,963,903 Magnetic core for medical procedures 2 2005
* 2007/0027,353 Magnetic core for medical procedures 16 2005
8,118,722 Reducing discomfort caused by electrical stimulation 0 2005
* 2006/0122,454 Reducing discomfort caused by electrical stimulation 32 2005
7,560,058 Magnetic core for medical procedures 4 2006
* 2007/0027,354 Magnetic core for medical procedures 6 2006
8,506,468 Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators 0 2008
* 2008/0224,808 FERROFLUIDIC COOLING AND ACOUSTICAL NOISE REDUCTION IN MAGNETIC STIMULATORS 10 2008
9,308,386 Magnetic core for medical procedures 0 2009
8,657,731 Magnetic core for medical procedures 3 2009
* 2009/0247,808 MAGNETIC CORE FOR MEDICAL PROCEDURES 0 2009
* 2009/0240,096 MAGNETIC CORE FOR MEDICAL PROCEDURES 4 2009
8,246,529 Magnetic core for medical procedures 2 2010
8,517,908 Reducing discomfort caused by electrical stimulation 1 2012
8,864,641 Reducing discomfort caused by electrical stimulation 0 2013
 
ALLERGAN, INC. (1)
* 2004/0254,251 Memantine oral dosage forms 12 2004
 
Depomed, Inc. (2)
9,000,046 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 0 2011
9,301,934 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 0 2015
 
BOSTON SCIENTIFIC NEUROMODULATION CORPORATION (1)
* 2004/0225,335 Treatment of Huntington's disease by brain stimulation 28 2004
 
SYNC-THINK, INC. (1)
9,265,458 Application of smooth pursuit cognitive testing paradigms to clinical drug development 0 2012
 
NeurOp, Inc. (2)
8,420,680 NMDA receptor antagonists for neuroprotection 0 2008
9,079,852 NMDA receptor antagonists for neuroprotection 0 2013
* Cited By Examiner